High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register

Florenzo Iannone, Elisa Gremese, Gaia Gallo, Piercarlo Sarzi-Puttini, Costantino Botsios, Francesco Trotta, Stefania Gasperini, Mauro Galeazzi, Silvano Adami, Fabrizio Cantini, Marco Sebastiani, Roberto Gorla, Antonio Marchesoni, Annarita Giardina, Rosario Foti, Angiola Mele, Eleonora Bruschi, Gianluca Bagnato, Gian Luca Erre, Giovanni LapadulaCrescenzio Scioscia, Anna Laura Fedele, Gianfranco Ferraccioli, Fabiola Atzeni, Sara Bongiovanni, Leonardo Punzi, Livio Bernardi, Valentina Bagnari, Marcello Govoni, Walter Grassi, Fausto Salaffi, Stefania Manganelli, Elena Frati, Antonio Carletto, Cristian Caimmi, Alice Palloni, Laura Niccoli, Clodoveo Ferri, Ennio Giulio Favalli, Giovanni Triolo, Marcella Di Gangi

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to evaluate the clinical outcomes of etanercept in rheumatoid arthritis (RA) patients with moderate or severe disease activity. We analyzed data from the Italian biologics register Gruppo Italiano Studio Early Arthritides (GISEA) to investigate the rate of disease remission and functional improvement, based on the 28-Joint Disease Activity Score (DAS28) and the (Health Assessment Questionnaire (HAQ) score in RA patients with moderate or severe disease activity beginning etanercept therapy. Disease was defined as severe (H-RA) withDAS28 ≥5.1 and moderate (M-RA) with DAS28 =3.2 to 5.1 at baseline. Patients were considered in remission if DAS28 was ≤2.6, and HAQ ≤0.5 defined normal function. We enrolled 953 RA patients, 320 with M-RA and 633 H-RA. Age and disease duration were similar in the two cohorts, but H-RA patients had significantly more comorbidities (p

Original languageEnglish
Pages (from-to)31-37
Number of pages7
JournalClinical Rheumatology
Volume33
Issue number1
DOIs
Publication statusPublished - 2014

Keywords

  • DAS28
  • Disease remission
  • GISEA
  • HAQ
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register'. Together they form a unique fingerprint.

Cite this